Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04022577
Other study ID # YM108024E
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2018
Est. completion date September 30, 2019

Study information

Verified date October 2023
Source National Yang Ming University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will explore the effect of Adherence Therapy(AT) on medication adherence in patients with schizophrenia spectrum disorder.


Description:

A single-blind, randomized controlled trial with a repeated-measures, two parallel groups design will be conducted for 120 participants with schizophrenia spectrum in regional hospital in northern Taiwan. After baseline data collection finished, the blocked randomization will be employed to assign participants to two groups. The experimental group will participate in a eight session course of Adherence Therapy. The control group received routine care. The data will be collected for baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks). A structured Questionnaire will use to collect data on the Medication Adherence Rating Scale, Schedule for the Assessment of Insight, Internalized Stigma of Mental Illness Scale, Self-Appraisal of Illness Questionnaire and Positive and Negative Syndrome Scale. Data analysis will employ Statistical Package for the Social Sciences 20.0 with Generalized estimating equations approach to examine effects of Adherence Therapy and routine care on medication adherence.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date September 30, 2019
Est. primary completion date August 30, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 64 Years
Eligibility Inclusion Criteria: - aged 20-64 - were Chinese speaking or Taiwanese speaking; - diagnosed with schizophrenia or schizoaffective disorder - recent history of non-adherence to antipsychotic medication. 1. Non-adherence to medication was defined as a recent history of cessation of psychiatric admission for more than one month at a time 2. The patient recently (half year) relapse of mental illness 3. Family and Health care worker state that the patient has taken irregular medication - demonstrated cognitive understanding of the research plan and provided consent. Exclusion Criteria: - discharged from hospital for at least 3 months - no intellectual disability, organic brain diseases or Cognitive impairment - no alcohol or sub-stance abuse problems - were not attending medication management program .

Study Design


Intervention

Behavioral:
Adherence Therapy
Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
control group
The control group received routine care

Locations

Country Name City State
Taiwan National Yang-Ming University Taipei City

Sponsors (2)

Lead Sponsor Collaborator
National Yang Ming University Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Medication Adherence Rating Scale The Medication Adherence Rating Scale was developed by Thompson et al. (2000). It evaluates the adherence behavior and attitude of the patient within the previous week. There are 10 close-ended questions (yes/no answers) in the questionnaire. for two study groups at baseline(T0) and after 4 session interim analysis (T1;9-12 weeks) and 8 session after intervention (T2;21-28 weeks).
Secondary Schedule for the Assessment of Insight, SAI The Schedule of Assessment of Insight (SAI) measures multiple dimensions of insight, including compliance with treatment, recognition of illness, re-labeling of psychotic phenomena, and awareness of changes in mental functioning and psychosocial consequences of the illness.The maximum score of the SAI is 14, with higher SAI scores indicating greater insight. The Cronbach alpha for the SAI was 0.96, and inter-rater reliability (r) between the two research psychiatrists was .92 in the present study. for two study groups at baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks).
Secondary Positive and Negative Syndrome Scale, PANSS PANSS assessed the severity of psychotic symptoms in terms of three subscales, including positive symptoms (hallucinations,delusional beliefs, and 30-item 7point Likert scale (from 1-'Absent' to 7-'Extremely'). for two study groups at baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks).
Secondary Self-Appraisal of Illness Questionnaire, SAIQ The Self-Appraisal of Illness Questionnaire (SAIQ) was used to assess patients' insight into their illness.The need for treatment and presence/outcome of illness subscales of SAIQ have been used as brief screening instruments for schizophrenic patients who may be at risk for treatment noncompliance. Lower SAIQ subscale scores indicate reduced awareness of the psychiatric illness. This scale is a self reporting instrument composed of 17 items in which participants are asked to rate the extent to which they agreed with each statement by using a 4-point Likert scale ranging from 0 (ie, "do not agree at all") to 3 (ie, "agree completely").
The internal consistency of the scale was 0.867, and the retest reliability was 0.82.
for two study groups at baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks).
See also
  Status Clinical Trial Phase
Completed NCT04709640 - Pilot Study to Improve Medication Management in Older Adults N/A
Completed NCT03257579 - Myocardial Infarction Prescription Duration Adherence Study N/A
Completed NCT05376397 - Testing THRIVE 365 for Black Sexual Minority Men (On The Daily) N/A
Withdrawn NCT03427008 - A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients N/A
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Withdrawn NCT03292393 - Social Norms and Antihypertensive Medication Adherence N/A
Completed NCT02823795 - The Supporting Patient Activation in Transition to Home Intervention N/A
Not yet recruiting NCT02876848 - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study) N/A
Completed NCT02914730 - Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections
Completed NCT02066935 - Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study
Completed NCT02797262 - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System N/A
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Completed NCT01770314 - Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication. Phase 2
Completed NCT01741311 - Secondary HIV Prevention and Adherence Among HIV-infected Drug Users N/A
Recruiting NCT01105104 - An Enhanced Medication Monitoring Program Phase 1
Withdrawn NCT01430702 - Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults N/A
Completed NCT01859273 - Adherence Enhancement for Renal Transplant Patients N/A
Completed NCT01118208 - Blister Packaging Medication to Increase Treatment Adherence and Clinical Response N/A
Completed NCT00848224 - Improving Adherence to Pharmacological Treatment N/A
Completed NCT06034301 - Pill Bottle vs Reminder App N/A